BioMarin Pharma (BMRN) Misses Q4 EPS Views

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/13/2026

1. WDAY
2. JNJ
3. AAPL
4. META
5. NRIX
6. SUNS
7. CRDO
8. OIG
9. SPY
10. SNDX

Go back to BioMarin Pharma (BMRN) Misses Q4 EPS Views

BioMarin Announces Fourth Quarter and Full Year 2015 Financial Results

February 25, 2016 4:02 PM EST

- Full-year 2015 Total BioMarin Revenue Increases 18.8% to $889.9 million Year-over-Year

- Vimizim Net Product Revenue Contributes Over $228 million to 2015 Top-line

- Full-year 2016 Total BioMarin Revenue Guidance of Between $1.05 billion to $1.10 billion

- Company Anticipates Non-GAAP Breakeven or Better in 2017 Under all E.U. Outcomes with Kyndrisa

Financial Highlights ($ in millions, except per share data, unaudited)

  Three Months Ended December 31,  Twelve Months... More